Abstract
Hydroxychloroquine, mycophenolate mofetil (MMF), and methotrexate (MTX) are common agents used to treat lichen planopilaris (LPP). However, there are no FDA-approved therapies for LPP, and the therapeutic efficacy of these agents is not well-described. We sought to evaluate the use and efficacy of these agents. We performed a retrospective chart review of patients at Wake Forest Baptist Health who received MMF, MTX, or hydroxychloroquine from 8/2020 to 8/2021 for LPP. A total of 31 patients ages 40-60 were included.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
